Alimera Sciences Inc (NASDAQ;ALIM) provided additional Phase III data in early February showing that its intravitreal insert (“Iluvien”), which provides sustained sub-microgram levels of fluocinolone acetonide, demonstrated significant improvements in the percentage of patients whose BCVA improved by equal or greater than 15 letters from baseline at months 30 and 33, compared to sham control, and non-significant improvements out to month 36 (FAME Study). The data follows up on an FDA letter in December 2010 seeking further analyses of safety and efficacy.